Artiva Biotherapeutics (NASDAQ:ARTV – Get Free Report) was upgraded by Wall Street Zen from a “strong sell” rating to a “sell” rating in a report released on Sunday, Wall Street Zen reports.
Other analysts have also issued reports about the company. Needham & Company LLC lowered Artiva Biotherapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, October 27th. Wedbush downgraded Artiva Biotherapeutics from an “outperform” rating to a “neutral” rating and set a $4.00 price objective on the stock. in a research note on Tuesday, October 27th. Cantor Fitzgerald reissued an “overweight” rating and issued a $40.00 price objective on shares of Artiva Biotherapeutics in a report on Friday, October 2nd. Jefferies Financial Group cut Artiva Biotherapeutics from a “buy” rating to a “hold” rating and set a $4.00 price target for the company. in a research report on Thursday, October 29th. Finally, TD Cowen lowered Artiva Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 27th. Two analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $24.80.
View Our Latest Stock Report on Artiva Biotherapeutics
Artiva Biotherapeutics Stock Down 1.2%
Artiva Biotherapeutics (NASDAQ:ARTV – Get Free Report) last posted its earnings results on Monday, November 9th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.01). Equities analysts predict that Artiva Biotherapeutics will post -2.74 EPS for the current year.
Insider Buying and Selling
In other news, CEO Fred Aslan sold 23,463 shares of the company’s stock in a transaction that occurred on Tuesday, October 6th. The stock was sold at an average price of $7.20, for a total transaction of $168,933.60. Following the transaction, the chief executive officer owned 1,519,606 shares of the company’s stock, valued at approximately $10,941,163.20. This represents a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Christopher Horan sold 10,340 shares of the stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $6.84, for a total value of $70,725.60. Following the completion of the sale, the insider owned 312,744 shares in the company, valued at approximately $2,139,168.96. The trade was a 3.20% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 136,619 shares of company stock worth $1,081,019. 1.80% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Artiva Biotherapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. RA Capital Management L.P. boosted its stake in Artiva Biotherapeutics by 3.0% in the third quarter. RA Capital Management L.P. now owns 18,489,293 shares of the company’s stock valued at $131,644,000 after acquiring an additional 533,651 shares in the last quarter. 5AM Venture Management LLC acquired a new stake in shares of Artiva Biotherapeutics in the second quarter valued at about $22,827,049. Blue Owl Capital Holdings LP acquired a new position in Artiva Biotherapeutics in the 2nd quarter valued at $8,483,000. BlackRock Inc. acquired a new position in Artiva Biotherapeutics in the 2nd quarter valued at about $6,739,000. Finally, State Street Corp grew its position in Artiva Biotherapeutics by 2.5% in the 3rd quarter. State Street Corp now owns 339,761 shares of the company’s stock valued at $2,419,000 after acquiring an additional 8,233 shares in the last quarter.
Artiva Biotherapeutics Company Profile
Artiva Biotherapeutics is a San Diego-based clinical-stage biotechnology company developing allogeneic, or donor-derived, natural killer (NK) cell therapies. Its approach is designed to provide ready-made cell treatments for patients with cancer and autoimmune diseases. The company’s lead candidate, AlloNK (also known as AB-101), is an investigational NK cell therapy being studied in combination with antibody treatments. Artiva is evaluating its potential in autoimmune conditions and in cancers, including B-cell malignancies.
Recommended Stories
- Five stocks we like better than Artiva Biotherapeutics
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Artiva Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artiva Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
